---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-21-033839"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2021-10-06T23:59:59+00:00"
generated_at: "2026-06-28T22:33:14.675601+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech terminates CFO, hires Hill; completes Phase 2 enrollment in head and neck cancer

## Summary
- CFO Seth Van Voorhees terminated without cause Sept 30; CEO Bedu-Addo interim CFO, controller Trochimiuk interim PAO.
- Matthew Hill appointed CFO effective Oct 18; salary $350k, 35% bonus, severance 12 mo base, inducement option for 202,800 shares.
- Completed enrollment of first stage of CPI-naïve arm in VERSATILE-002 Phase 2 study for HPV16 head and neck cancer.
- If >=4 of first 17 patients achieve objective response per RECIST 1.1, arm advances to second stage with total 54 patients; trial with Merck.

## SEC filing metadata
- accession: 0001140361-21-033839
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2021-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/0001140361-21-033839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/brhc10029650_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-21-033839
- JSON: https://secwatch.observer/filing/0001140361-21-033839.json
- Plain text: https://secwatch.observer/filing/0001140361-21-033839.txt

## Key facts
- Executive change
  Matthew Hill was appointed as Chief Financial Officer at PDS Biotechnology Corp.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On October 4, 2021, the Company entered into an Executive Employment Agreement with Matthew Hill (the “ Employment Agreement ”), pursuant to which Mr. Hill will be appointed as the Company’s Chief Financial Officer, effective as of October 18, 2021 (the “ Effective Date ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/0001140361-21-033839-index.htm
- Executive change
  Janetta Trochimiuk changed role as interim principal accounting officer at PDS Biotechnology Corp.
  - Action: will serve as interim principal accounting officer
  - Role: interim principal accounting officer
  source text: Janetta Trochimiuk, the Company’s controller, will serve as the interim principal accounting officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/0001140361-21-033839-index.htm
- Executive change
  Frank Bedu-Addo changed role as interim principal financial officer at PDS Biotechnology Corp.
  - Action: will serve as interim principal financial officer
  - Role: interim principal financial officer
  source text: Frank Bedu-Addo, the Company’s Chief Executive Officer, will serve as the Company’s interim principal financial officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/0001140361-21-033839-index.htm
- Executive change
  Seth Van Voorhees departed as Chief Financial Officer, principal financial officer and principal accounting officer at PDS Biotechnology Corp.
  - Action: terminated without cause
  - Role: Chief Financial Officer, principal financial officer and principal accounting officer
  source text: On September 30, 2021, PDS Biotechnology Corporation (the “ Company ”) delivered a notice of termination without cause to Seth Van Voorhees and removed him from his position as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/0001140361-21-033839-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.